journal article·2025-07-16Open access

Nanofibrillar Cellulose Hydrogels with Anionic Surface Modifications for Modulating Macrophage Phenotype in 3D Culture

Maria Heilala, Rita Turpin, Nikolaos Pahimanolis, Nonappa, Olli Ikkala, Juha Klefström, Pauliina M. Munne

ACS Applied Materials & Interfaces· Volume 17· Issue 28

Abstract

High Resolution Image Download MS PowerPoint Slide Anti-inflammatory M2 macrophages are highly relevant in various physiological processes ranging from tissue regeneration to cancer progression. However, conventional two-dimensional (2D) in vitro cell cultures limit our understanding of macrophage phenotypes and how they can be modulated for immunotherapeutic approaches. Moreover, there is a growing demand for scalable, animal-free hydrogels to replace animal-derived materials in three-dimensional (3D) in vitro models. In this study, we explore hydrogels based on plant-derived nanofibrillar cellulose (NFC), also known as cellulose nanofibrils (CNFs) or microfibrillated cellulose (MFC), for generating 3D in vitro models of M2-like macrophages from human blood monocytes. Notably, flow cytometry analysis shows that cells cultured in 3D phosphorylated NFC hydrogels show enhanced expression of the M2 macrophage marker CD206 compared to cells cultured in other negatively charged hydrogels prepared from native NFC or NFCs with carboxylate or sulfate modifications. Furthermore, the upregulation of CD206 expression in 3D phosphorylated NFC is comparable to the induction of CD206 in interleukin 4 (IL-4)-differentiated M2a macrophages. In addition, the cells in the phosphorylated NFC hydrogel show a differential cytokine profile compared to 2D cultured cells, secreting similar levels of tumor necrosis factor α (TNF-α), but 2.6-fold higher amounts of IL-1β and 1.2-fold higher amounts of IL-10. The results suggest that the conversion of monocytes to M2-like macrophages can be controlled by the phosphorylation of NFC, a strategy which does not require the addition of polarization factors like growth factors and cytokines conventionally used to generate macrophages in vitro . The findings highlight the importance of surface chemistry in matrix-guided macrophage polarization, paving the way for xeno-free yet bioactive 3D macrophage culture scaffolds for immunological research.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Immune cells in cancer · Graphene and Nanomaterials Applications · 3D Printing in Biomedical Research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Applied Physics, Aalto University. P.O. Box 15100, FI-00076 Aalto, Espoo Finland

Cancer Cell Circuitry Laboratory, Translational Cancer Medicine, Medical Faculty, University of Helsinki. P.O. Box 63, Haartmaninkatu 8, FI-00014 Helsinki, Finland

Oy Keskuslaboratorio-Centrallaboratorium Ab, Tekniikantie 2, FI-02150 Espoo, Finland

Faculty of Engineering and Natural Sciences

Tampere University

Finnish Cancer Institute

FICAN South, Helsinki University Hospital, FI-00290, HUS, Helsinki, Finland

Department of Cell & Tissue Biology, Universityof California, San Francisco, 513 Parnassus Avenue, UCSF Campus Box 0512, San Francisco, California 94143, United States

Funding

Tekniikan Edistämissäätiö · Sigrid Juséliuksen Säätiö · H2020 Health · Research Council of Finland · Syöpäsäätiö · Business Finland · Finnish Cancer Institute · Office of the Assistant Secretary of Defense for Health Affairs

References (100+)

Show source-provided references
1. 10.1038/nature1203410.1038/nature12034 ↗
2. 10.2741/269210.2741/2692 ↗
3. 10.1038/s41698-024-00522-z10.1038/s41698-024-00522-z ↗
4. 10.1038/bjc.2017.35610.1038/bjc.2017.356 ↗
5. 10.3389/fbioe.2024.129188010.3389/fbioe.2024.1291880 ↗
6. 10.1016/j.jconrel.2016.01.02610.1016/j.jconrel.2016.01.026 ↗
7. Heideveld E. · 2020 · 632 · 113
8. 10.1016/j.imbio.2014.05.00210.1016/j.imbio.2014.05.002 ↗
9. 10.1016/j.immuni.2014.06.00810.1016/j.immuni.2014.06.008 ↗
10. 10.1002/adhm.20180067510.1002/adhm.201800675 ↗
11. 10.1021/acsami.0c1650910.1021/acsami.0c16509 ↗
12. 10.1016/j.actbio.2019.02.04810.1016/j.actbio.2019.02.048 ↗
13. 10.1016/j.mtbio.2023.10089710.1016/j.mtbio.2023.100897 ↗
14. 10.1073/pnas.130888711010.1073/pnas.1308887110 ↗
15. 10.1111/imr.1222310.1111/imr.12223 ↗
16. 10.1038/s41467-023-38093-510.1038/s41467-023-38093-5 ↗
17. 10.1016/j.ajpath.2019.06.00510.1016/j.ajpath.2019.06.005 ↗
18. 10.1016/j.immuni.2014.01.00610.1016/j.immuni.2014.01.006 ↗
19. 10.1038/nmeth.383910.1038/nmeth.3839 ↗
20. 10.1021/acsami.1c0254210.1021/acsami.1c02542 ↗
21. 10.1002/adhm.20160096710.1002/adhm.201600967 ↗
22. 10.1002/adhm.20180123410.1002/adhm.201801234 ↗
23. 10.1111/j.1365-313X.2008.03463.x10.1111/j.1365-313X.2008.03463.x ↗
24. 10.1016/j.progpolymsci.2018.09.00210.1016/j.progpolymsci.2018.09.002 ↗
25. 10.1002/smsc.20220007610.1002/smsc.202200076 ↗
26. 10.1002/anie.20100127310.1002/anie.201001273 ↗
27. 10.1016/0014-4827(92)90397-Q10.1016/0014-4827(92)90397-Q ↗
28. 10.1016/j.jconrel.2012.06.03910.1016/j.jconrel.2012.06.039 ↗
29. 10.1089/scd.2013.031410.1089/scd.2013.0314 ↗
30. 10.1016/j.actbio.2020.03.00710.1016/j.actbio.2020.03.007 ↗
31. 10.1021/acs.biomac.1c0057910.1021/acs.biomac.1c00579 ↗
32. 10.1002/jev2.1227310.1002/jev2.12273 ↗
33. 10.1016/j.carbpol.2022.11929910.1016/j.carbpol.2022.119299 ↗
34. 10.1186/s12989-016-0182-010.1186/s12989-016-0182-0 ↗
35. 10.1007/s10570-011-9501-710.1007/s10570-011-9501-7 ↗
36. 10.1007/s10570-015-0772-210.1007/s10570-015-0772-2 ↗
37. 10.1007/s10570-014-0524-810.1007/s10570-014-0524-8 ↗
38. 10.1016/j.intimp.2011.02.01610.1016/j.intimp.2011.02.016 ↗
39. 10.1021/acs.biomac.5b0072710.1021/acs.biomac.5b00727 ↗
40. 10.2147/IJN.S18351010.2147/IJN.S183510 ↗
41. Nuopponen, M.; Paasonen, L.; Narkilahti, S.; Joki, T. Ylä-Uotinen (Upm-Kymmene Corporation L. WO Patent, WO2018234634A1, 2018 https://patents.google.com/patent/WO2018234634A1/en. (accessed December 05, 2023).
42. 10.1038/nmeth.201910.1038/nmeth.2019 ↗
43. 10.1016/j.carbpol.2010.12.02910.1016/j.carbpol.2010.12.029 ↗
44. 10.1007/s10570-019-02922-y10.1007/s10570-019-02922-y ↗
45. 10.1021/bm200968510.1021/bm2009685 ↗
46. 10.1007/s10570-021-04012-410.1007/s10570-021-04012-4 ↗
47. 10.1039/C9RA01447K10.1039/C9RA01447K ↗
48. 10.1021/acs.biomac.3c0026110.1021/acs.biomac.3c00261 ↗
49. 10.1002/adma.20200605210.1002/adma.202006052 ↗
50. 10.1093/rb/rbac00910.1093/rb/rbac009 ↗
51. 10.1002/jbm.b.3308810.1002/jbm.b.33088 ↗
52. 10.1038/s41467-021-27220-910.1038/s41467-021-27220-9 ↗
53. 10.1002/adhm.20230113710.1002/adhm.202301137 ↗
54. 10.1007/s10570-012-9766-510.1007/s10570-012-9766-5 ↗
55. 10.1021/acs.biomac.6b0066810.1021/acs.biomac.6b00668 ↗
56. 10.15376/biores.12.4.Hubbe10.15376/biores.12.4.Hubbe ↗
57. 10.1007/s10570-022-04664-w10.1007/s10570-022-04664-w ↗
58. 10.1111/imm.1312510.1111/imm.13125 ↗
59. 10.1016/j.nantod.2024.10221510.1016/j.nantod.2024.102215 ↗
60. 10.1016/j.mucimm.2023.06.00610.1016/j.mucimm.2023.06.006 ↗
61. 10.1038/s41598-017-03780-z10.1038/s41598-017-03780-z ↗
62. 10.1023/A:101559323234710.1023/A:1015593232347 ↗
63. 10.1002/cyto.b.2128010.1002/cyto.b.21280 ↗
64. 10.1155/2015/81646010.1155/2015/816460 ↗
65. 10.1016/j.carbpol.2017.06.07310.1016/j.carbpol.2017.06.073 ↗
66. 10.1089/ten.2005.11.110.1089/ten.2005.11.1 ↗
67. 10.1158/2159-8290.CD-17-083310.1158/2159-8290.CD-17-0833 ↗
68. 10.1186/s12866-022-02623-w10.1186/s12866-022-02623-w ↗
69. 10.1002/jbm.a.3271410.1002/jbm.a.32714 ↗
70. 10.1002/jbm.a.3164910.1002/jbm.a.31649 ↗
71. 10.1016/j.biomaterials.2019.11966710.1016/j.biomaterials.2019.119667 ↗
72. 10.1016/j.msec.2019.10988310.1016/j.msec.2019.109883 ↗
73. 10.1089/ten.teb.2018.005610.1089/ten.teb.2018.0056 ↗
74. 10.1021/acs.biomac.6b0005310.1021/acs.biomac.6b00053 ↗
75. 10.1016/j.carbpol.2024.12247910.1016/j.carbpol.2024.122479 ↗
76. 10.1007/s10570-021-04154-510.1007/s10570-021-04154-5 ↗
77. 10.1016/j.ijbiomac.2023.12684210.1016/j.ijbiomac.2023.126842 ↗
78. 10.1016/j.smim.2007.11.00410.1016/j.smim.2007.11.004 ↗
79. 10.1016/j.jcis.2020.09.08010.1016/j.jcis.2020.09.080 ↗
80. 10.1021/acsami.5c0039110.1021/acsami.5c00391 ↗
81. 10.1021/acsabm.2c0079410.1021/acsabm.2c00794 ↗
82. 10.1021/acs.biomac.4c0026410.1021/acs.biomac.4c00264 ↗
83. 10.1146/annurev.immunol.23.021704.11581610.1146/annurev.immunol.23.021704.115816 ↗
84. 10.1038/s41467-020-17639-x10.1038/s41467-020-17639-x ↗
85. 10.4049/jimmunol.180155910.4049/jimmunol.1801559 ↗
86. 10.1161/CIRCRESAHA.109.21571510.1161/CIRCRESAHA.109.215715 ↗
87. 10.1189/jlb.060837110.1189/jlb.0608371 ↗
88. 10.1096/fj.06-5742com10.1096/fj.06-5742com ↗
89. 10.1039/C5NR03884G10.1039/C5NR03884G ↗
90. 10.1038/ncomms872210.1038/ncomms8722 ↗
91. 10.1016/S1367-5931(00)00153-810.1016/S1367-5931(00)00153-8 ↗
92. 10.1189/jlb.100556410.1189/jlb.1005564 ↗
93. 10.1016/j.immuni.2015.06.00310.1016/j.immuni.2015.06.003 ↗
94. 10.1002/smll.20190164210.1002/smll.201901642 ↗
95. 10.1002/smll.20210254510.1002/smll.202102545 ↗
96. 10.1021/acsabm.9b0107310.1021/acsabm.9b01073 ↗
97. 10.1016/j.carbpol.2022.11920810.1016/j.carbpol.2022.119208 ↗
98. 10.1021/acsabm.2c0085410.1021/acsabm.2c00854 ↗
99. 10.1002/mabi.20170023610.1002/mabi.201700236 ↗
100. 10.1016/j.ijpharm.2017.09.00210.1016/j.ijpharm.2017.09.002 ↗